Efficacy and tolerability of peginterferon α -2a and peginterferon α -2b, both plus ribavirin, for chronic hepatitis C: A meta-analysis of randomized controlled trials

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Yang, Zongguo ^a   Zhuang, Liping ^a,b   Yang, Lei ^c   Chen, Xiaorong ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c CHINA AEROSPACE SCIENCE AND INDUSTRY CORPORATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

COCHRANE LIBRARY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84877251221     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/739029     Document Type: Review

References (41)

1. Omata M., Kanda T., Yu M. L., APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International 2012 6 409 435
2. European Association for the Study of the Liver, EASL clinical practice guidelines:management of hepatitis C virus infection. Journal of Hepatology 2011 55 2 245 264
3. Seeff L. B., The history of the "natural history" of hepatitis C (1968-2009). Liver International 2009 29 supplement 1 89 99 2-s2.0-59149083248 10.1111/j.1478-3231.2008.01927.x
4. Schaefer E. A. K., Chung R. T., Anti-hepatitis C virus drugs in development. Gastroenterology 2012 142 1340 1350
5. Yenice N., Mehtap O., Gümrah M., Arican N., The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology 2006 17 2 94 98 2-s2.0-34147163958 (Pubitemid 46567826)
6. Di Bisceglie A. M., Ghalib R. H., Hamzeh F. M., Rustgi V. K., Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis 2007 14 10 721 729 2-s2.0-34548660545 10.1111/j.1365-2893. 2007.00862.x (Pubitemid 47414932)
7. Scotto G., Fazio V., Fornabaio C., Tartaglia A., Tullio R. D., Saracino A., Angarano G., Peg-Interferon alpha-2a versus Peg-Interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. Journal of Interferon and Cytokine Research 2008 28 10 623 630 2-s2.0-54249139151 10.1089/jir.2007.0116
8. McHutchison J. G., Lawitz E. J., Shiffman M. L., Muir A. J., Galler G. W., McCone J., Nyberg L. M., Lee W. M., Ghalib R. H., Schiff E. R., Galati J. S., Bacon B. R., Davis M. N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L. D., Brass C. A., Albrecht J. K., Sulkowski M. S., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine 2009 361 6 580 593 2-s2.0-68249154875 10.1056/NEJMoa0808010
9. Rumi M. G., Aghemo A., Prati G. M., D'Ambrosio R., Donato M. F., Soffredini R., Del Ninno E., Russo A., Colombo M., Randomized study of peginterferon- α 2a plus ribavirin vs peginterferon- α 2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010 138 1 108 115 2-s2.0-72249083270 10.1053/j.gastro.2009.08.071
10. Ascione A., De Luca M., Tartaglione M. T., Lampasi F., Di Costanzo G. G., Lanza A. G., Picciotto F. P., Marino-Marsilia G., Fontanella L., Leandro G., Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010 138 1 116 122 2-s2.0-72249094116 10.1053/j.gastro.2009.10. 005
11. Mach T. H., Cieśla A., Warunek W., Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej 2011 121 12 434 439
12. Zhao S. H., Liu E. Q., Chen P., A comparison of peginterferon α -2a and α -2b for treatment-naïve patients with chronic hepatitis C virus: a meta-analysis of randomized trials. Clinical Therapeutics 2010 32 1565 1577
13. Awad T., Thorlund K., Hauser G., Stimac D., Mabrouk M., Gluud C., Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2B in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010 51 4 1176 1184 2-s2.0-77950622393 10.1002/hep.23504
14. Singal A. K., Jampana S. C., Anand B. S., Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Digestive Diseases and Sciences 2011 56 8 2221 2226 2-s2.0-79960970207 10.1007/s10620-011-1765-0
15. Alavian S. M., Behnava B., Tabatabaei S. V., The comparative efficacy and safety of peginterferon Alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepatitis Monthly 2010 10 2 121 131 2-s2.0-77954881726
16. Higgins J. P. T., Green S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011 The Cochrane Collaboration. http://handbook.cochrane.org/
17. Higgins J. P. T., Thompson S. G., Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002 21 11 1539 1558 2-s2.0-0037098199 10.1002/sim.1186 (Pubitemid 34746062)
18. Berak H., Horban A., Wasilewski M., Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2a vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes-12 Week virological response analysis. Hepatology 2005 42 684A
19. Kolakowska-Rzadzko A., Berok H., Wasilewski M., Horbon A., Relevance between fibrosis and response to treatment with peginterferon alfa 2a vs alfa 2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology 2008 48 A878
20. Sinha S., Gulur P., Patel V., Hage-Nassar G., Tenner S., A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. The American Journal of Gastroenterology 2004 99, supplement S77 S78
21. Khan A. Q., Awan A., Shahbuddin S., Igbal Q., Peginterferon alfa 2a/ribavirin versus peginterferon alfa 2b/ribavirin combination therapy in chronic hepatitis C genotype 3. Gastroenterology 2007 132 A200
22. Kamal S., Ghoraba D., Nabegh L., Pegylated interferon alfa-2A vs. pegylated interferon alfa-2B, plus ribavirin for chronic hepatitis C genotype 4 patients: a randomized controlled trial. Hepatology 2009 50 A1025 A1026
23. Magni C., Niero F., Argenteri B., Antiviral activity and tolerability between pegylated interferon alpha 2a and alpha 2b in naive patients with chronic hepatitis C: results of a prospective monocentric randomized trial. Hepatology 2009 50 A720
24. Silva M., Poo J., Wagner F., Jackson M., Cutler D., Grace M., Bordens R., Cullen C., Harvey J., Laughlin M., A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology 2006 45 2 204 213 2-s2.0-33745713376 10.1016/j.jhep.2006. 03.008
25. Lee S., Kim I. H., Kim S. H., Kim S. W., Lee S. O., Lee S. T., Kim D. G., Lee C. S., Choi C. S., Cho E. Y., Kim H. C., Efficacy and tolerability of pegylated interferon- α 2a plus ribavirin versus pegylated interferon- α 2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010 53 3 146 153 2-s2.0-73649102116 10.1159/000274975
26. Bruno R., Sacchi P., Ciappina V., Zochetti C., Patruno S., Maiocchi L., Filice G., Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy 2004 9 4 491 497 2-s2.0-4344625164 (Pubitemid 39150205)
27. Laguno M., Cifuentes C., Murillas J., Veloso S., Larrousse M., Payeras A., Bonet L., Vidal F., Milinkovic A., Bassa A., Villalonga C., Pérez I., Tural C., Martínez-Rebollar M., Calvo M., Blanco J. L., Martínez E., Sánchez-Tapias J. M., Gatell J. M., Mallolas J., Randomized trial comparing pegylated interferon -2b versus pegylated interferon -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009 49 1 22 31 2-s2.0-58949099266 10.1002/hep.22598
28. Scotto G., Fazio V., Fornabaio C., Tartaglia A., Di Tullio R., Saracino A., Angarano G., Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon- α -2a versus pegylated interferon- α -2b. Drugs 2008 68 6 791 801 2-s2.0-42249091065 (Pubitemid 351550531)
29. Coppola N., Pisaturo M., Sagnelli C., Efficacy and tolerability peginterferon a-2a and a-2b in patients with chronic hepatitis C by genotype 1: a meta-analysis. Digestive and Liver Diseases 2011 43, supplement S94
30. Kau A., Vermehren J., Sarrazin C., Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 2008 49 4 634 651 2-s2.0-50649112802 10.1016/j.jhep.2008.07.013
31. Ghany M. G., Strader D. B., Thomas D. L., Seeff L. B., Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 4 1335 1374 2-s2.0-65449136656 10.1002/hep.22759
32. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales J. F. L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002 347 13 975 982 2-s2.0-0037179698 10.1056/NEJMoa020047
33. Hadziyannis S. J., Sette H. Jr., Morgan T. R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P. J., Lin A., Ackrill A. M., Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004 140 5 346 I67 2-s2.0-1542378867
34. Rumi M., Aghemo A., Prati G. M., Comparative trials of peginterferon α -2a and peginterferon α -2b for chronic hepatitis C. Journal of Viral Hepatitis 2012 19 supplement 1 37 41
35. Hiramatsu N., Oze T., Yakushijin T., Inoue Y., Igura T., Mochizuki K., Imanaka K., Kaneko A., Oshita M., Hagiwara H., Mita E., Nagase T., Ito T., Inui Y., Hijioka T., Katayama K., Tamura S., Yoshihara H., Imai Y., Kato M., Yoshida Y., Tatsumi T., Ohkawa K., Kiso S., Kanto T., Kasahara A., Takehara T., Hayashi N., Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. Journal of Viral Hepatitis 2009 16 8 586 594 2-s2.0-68749109781 10.1111/j.1365-2893.2009.01106.x
36. Furusyo N., Murata M., Ogawa E., Toyoda K., Ihara T., Ikezaki H., Hayashi T., Koga T., Kainuma M., Hayashi J., Ribavirin concentration in the later stages of 48 week pegylated interferon- α 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Journal of Antimicrobial Chemotherapy 2011 66 5 1127 1139 2-s2.0-79954620612 10.1093/jac/dkr034
37. Zeuzem S., Welsch C., Herrmann E., Pharmacokinetics of peginterferons. Seminars in Liver Disease 2003 23 1 23 28 2-s2.0-0041317671 (Pubitemid 37052441)
38. Bruno R., Sacchi P., Scagnolari C., Torriani F., Maiocchi L., Patruno S., Bellomi F., Filice G., Antonelli G., Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology and Therapeutics 2007 26 3 369 376 2-s2.0-34447298143 10.1111/j.1365-2036.2007. 03392.x (Pubitemid 47063155)
39. Foster G. R., Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon- α -2a and peginterferon- α -2b. Drugs 2010 70 2 147 165 2-s2.0-75749146715 10.2165/11531990-000000000-00000
40. François C., Descamps V., Brochot E., Bernard I., Canva V., Mathurin P., Castelain S., Duverlie G., Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. Journal of Medical Virology 2010 82 10 1640 1646 2-s2.0-77956588887 10.1002/jmv.21837
41. Foster G. R., Review article: pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics 2004 20 8 825 830 2-s2.0-7044236793 10.1111/j.1365-2036.2004.02170.x (Pubitemid 39424889)